ClinicalTrials.gg
CompletedNCT04849559Updated Apr 16, 2024Results posted

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

A Phase 1/2 interventional study of Tradipitant and Placebo in Healthy Volunteer, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Vanda Pharmaceuticals · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the effects of tradipitant relative to placebo on satiation, gastric volume, gastric accommodation, and gastric emptying in healthy volunteers.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • tradipitant
  • NK-1 antagonist
  • neurokinin 1 receptor
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written consent
  • (BMI) of 18-35 kg/m2
  • No medical problems or chronic diseases

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of gastrointestinal diseases
  • Structural or metabolic diseases that affect the GI system
  • A positive test for drugs of abuse at screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Tradipitant

    Oral Capsule

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Oral Capsule

    Drug: Placebo

Interventions

  • Tradipitant Capsule

  • DrugPlacebo

    Placebo Capsule

06

What researchers measure

Primary outcomes

  1. Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT)

    Fasting Gastric volume

    Time frame: 9 Days

  2. Accommodation Volume as Measured by SPECT

    Gastric Accommodation post 300mL Ensure

    Time frame: 9 Days

  3. Satiation Expressed as Volume to Fullness as Measured by Satiation Test

    Time frame: 9 Days

  4. Gastric Emptying Half-time of Solids as Measured by Scintigraphy

    Gastric Emptying Solids, T50%, Min

    Time frame: 9 Days

07

Results

Posted Apr 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneTradipitantPlacebo
Started1314
Completed1113
Not completed21
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryFasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT)

Fasting Gastric volume

Time frame:
9 Days
Reported as:
Median · mL
Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT)
mLTradipitantPlacebo
Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT)178.8 (158.0 to 217.0)191.1 (169.2 to 216.9)
PrimaryAccommodation Volume as Measured by SPECT

Gastric Accommodation post 300mL Ensure

Time frame:
9 Days
Reported as:
Median · mL
Accommodation Volume as Measured by SPECT
mLTradipitantPlacebo
Accommodation Volume as Measured by SPECT423.8 (358.5 to 484.1)411.0 (358.3 to 476.3)
PrimarySatiation Expressed as Volume to Fullness as Measured by Satiation Test
Time frame:
9 Days
Reported as:
Median · mL
Satiation Expressed as Volume to Fullness as Measured by Satiation Test
mLTradipitantPlacebo
Satiation Expressed as Volume to Fullness as Measured by Satiation Test592.5 (474.0 to 829.5)711.0 (474.0 to 948.0)
PrimaryGastric Emptying Half-time of Solids as Measured by Scintigraphy

Gastric Emptying Solids, T50%, Min

Time frame:
9 Days
Reported as:
Median · minutes
Gastric Emptying Half-time of Solids as Measured by Scintigraphy
minutesTradipitantPlacebo
Gastric Emptying Half-time of Solids as Measured by Scintigraphy137.0 (106.8 to 145.0)134.0 (125.3 to 141.7)

Adverse events

Collected over 9 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant0/13 (0%)0/13 (0%)4/13 (30.8%)
Placebo0/14 (0%)0/14 (0%)4/14 (28.6%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTradipitantPlacebo
fatigueGeneral disorders2/131/14
somnolenceNervous system disorders2/131/14
peripheral swellingGeneral disorders1/130/14
diarrheaGastrointestinal disorders1/130/14
AcneSkin and subcutaneous tissue disorders1/130/14
headacheNervous system disorders1/131/14
disturbance in attentionNervous system disorders1/130/14
dizziness posturalNervous system disorders1/130/14
restless leg syndromeNervous system disorders1/130/14
depressed moodPsychiatric disorders1/130/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TradipitantPlaceboTotal
Mean32.5 ± 9.6134.9 ± 10.7033.7 ± 10.07
Sex: Female, Male
Sex: Female, Male(Participants)TradipitantPlaceboTotal
Female7613
Male6814
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TradipitantPlaceboTotal
Hispanic or Latino123
Not Hispanic or Latino121224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TradipitantPlaceboTotal
American Indian or Alaska Native000
Asian347
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6713
More than one race000
Unknown or Not Reported437
Region of Enrollment
Region of Enrollment(participants)TradipitantPlaceboTotal
United States131427
08

Study locations

1 site
  • Vanda Investigational Site
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Khanna L, Zheng T, Atieh J, Torres M, Busciglio I, Carlin JL, Xiao M, Harmsen WS, Camilleri M. Clinical trial: a single-centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers. Aliment Pharmacol Ther. 2022 Jul;56(2):224-230. doi: 10.1111/apt.17065. Epub 2022 May 29. PubMed 35644931 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Sep 2021, 7 months.

Results were first posted in Apr 2024, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 19, 2021
StartActual
Feb 1, 2021
Primary completionActual
Sep 24, 2021
CompletionActual
Sep 24, 2021
Results first posted
Apr 16, 2024
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04849559
Collaborators
Mayo Clinic
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Feb 1, 2021
Primary completion
Sep 24, 2021
Completion
Sep 24, 2021
Results posted
Apr 16, 2024
Last update
Apr 16, 2024

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion